Concolino G, Di Silverio F, Marocchi A, Bracci U
Eur Urol. 1979;5(2):90-3. doi: 10.1159/000473074.
The hypothesis of hormone dependence of human renal cancer, based on experimental and clinical data, has recently been supported by estradiol-receptor (ER) and progesterone-receptor (PR) studies. ER and PR, found in experimental renal cancer as well as in normal human kidney and in human renal cell carcinoma (RCC), have been measured in 27 RCCs from patients submitted to surgery and endocrine therapy, in an attempt to predict the response to progestational therapy . Of these 27 tumors, 59% were positive for ER and 59% for PR; 37% were positive and 19% were negative for both ER and PR. The follow-up of 23 patients so far investigated showed that progestational therapy, commenced in 18 patients, has given favorable results in 14 patients and negative results in 3 patients with ER-PR- renal cancer. Antiestrogenic therapy, started after nephrectomy in 1 patient with ER+PR- renal cancer and lung metastases, failed since the patient died 8 months after surgery.
基于实验和临床数据的人类肾癌激素依赖性假说，最近得到了雌二醇受体（ER）和孕酮受体（PR）研究的支持。在实验性肾癌以及正常人类肾脏和人类肾细胞癌（RCC）中发现的ER和PR，已在27例接受手术和内分泌治疗的患者的RCC中进行了检测，以试图预测对孕激素治疗的反应。在这27个肿瘤中，59%的ER呈阳性，59%的PR呈阳性；37%的ER和PR均呈阳性，19%的ER和PR均呈阴性。到目前为止对23例患者的随访表明，18例患者开始的孕激素治疗，在14例患者中取得了良好效果，在3例ER-PR-肾癌患者中取得了阴性结果。1例ER+PR-肾癌伴肺转移的患者在肾切除术后开始抗雌激素治疗，但该患者在手术后8个月死亡，治疗失败。
